hVIVO plc (AIM:HVO)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 40.53M -23.6% |
| Revenue (ttm) | 42.09M -25.0% |
| Net Income | -12.21M |
| EPS | -0.02 |
| Shares Out | 687.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,066,309 |
| Open | 6.00 |
| Previous Close | 5.90 |
| Day's Range | 5.80 - 6.00 |
| 52-Week Range | 4.31 - 11.00 |
| Beta | 1.66 |
| Analysts | Buy |
| Price Target | 15.50 (+161.21%) |
| Est. Earnings | Dec 16, 2026 |
About hVIVO
hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including virology, immunology and biomarker analysis, as well as assay development, sample analy... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for HVO stock is "Buy." The 12-month stock price target is 16p, which is an increase of 161.21% from the latest price.
News
Half Year 2026 hVIVO PLC Earnings Presentation Transcript
Half Year 2026 hVIVO PLC Earnings Presentation Transcript
hVIVO Earnings Call Transcript: H1 2026
Revenue for H1 2026 declined to GBP 16.3 million due to HCT contract delays, resulting in an EBITDA loss, but a record GBP 72 million order book and diversification into new service lines and geographies support strong visibility and projected growth for 2027. CRS Berlin acquisition is immediately accretive, and H2 2026 is expected to see nearly double the revenue of H1.
hVIVO Quarterly report: H1 2026
hVIVO has published its H1 2026 quarterly earnings report on September 15, 2026.
hVIVO Slides: H1 2026
hVIVO has posted slides in relation to its H1 2026 quarterly earnings report, which was published on September 15, 2026.
hVIVO Earnings release: H1 2026
hVIVO released its H1 2026 earnings on July 23, 2026, summarizing the period's financial results.
hVIVO Transcript: CMD 2026
The company has transformed into a fully integrated clinical development platform, expanding its service lines, geographic reach, and technological capabilities. Diversification and strategic partnerships have driven growth, with notable success in respiratory and cardiometabolic research, and a strong pipeline supported by repeat business and regulatory recognition of challenge trials.
hVIVO Slides: FY 2026
hVIVO has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 11, 2026.
Decoy Therapeutics Partners With HVIVO To Advance D-MAV Into Clinical Study; Stock Up
(RTTNews) - Decoy Therapeutics Inc. (DCOY), a pre-clinical stage biotechnology company, announced that it has entered into a strategic development agreement with a European based pharmaceutical servic...
Full Year 2025 hVIVO PLC Earnings Presentation Transcript
Full Year 2025 hVIVO PLC Earnings Presentation Transcript
hVIVO Earnings Call Transcript: H2 2025
2025 saw financial challenges from trial cancellations, but operational progress included acquisitions, rebranding, and diversification into new clinical and geographic areas. Human challenge trials remain core, but non-challenge revenue now exceeds 50%, supporting a strong outlook for 2026.
hVIVO Annual report: H2 2025
hVIVO has published its H2 2025 annual report on April 15, 2026.
hVIVO Slides: H2 2025
hVIVO has posted slides in relation to its H2 2025 quarterly earnings report, which was published on April 15, 2026.
hVIVO Annual report: H2 2025
hVIVO has published its H2 2025 annual report on April 15, 2026.
hVIVO Earnings Call Transcript: Q4 2025
FY25 revenue met guidance at GBP 46.7m, with positive EBITDA margin and strong cash position. Acquisitions expanded services and geographic reach, while diversification reduced reliance on HCT. Guidance for 2026 is high single-digit growth, supported by a robust pipeline.
hVIVO Earnings release: Q4 2025
hVIVO released its Q4 2025 earnings on January 29, 2026, summarizing the period's financial results.
hVIVO Slides: Q4 2025
hVIVO has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on January 29, 2026.
hVIVO upgraded to Buy from Add at Peel Hunt
Peel Hunt analyst Miles Dixon upgraded hVIVO (OPORF) to Buy from Add with a 10 GBp price target
Full Year 2024 hVIVO PLC Investor Presentation Transcript
Full Year 2024 hVIVO PLC Investor Presentation Transcript
Half Year 2025 hVIVO PLC Earnings Presentation Transcript
Half Year 2025 hVIVO PLC Earnings Presentation Transcript
hVIVO Earnings Call Transcript: H1 2025
Revenue for H1 2025 declined year-over-year, but acquisitions and diversification into new service lines partially offset the impact of headwinds in human challenge clinical trials. Cash remains strong, and guidance for 2025 is reiterated, with growth and profitability expected in 2026–2027.
hVIVO Quarterly report: H1 2025
hVIVO has published its H1 2025 quarterly earnings report on September 23, 2025.
hVIVO Slides: H1 2025
hVIVO has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 23, 2025.
hVIVO Earnings Call Transcript: H1 2025
H1 2025 saw £24.2m revenue and 12% EBITDA margin, with strong cash reserves and ongoing integration of CRS and Cryostore. Despite market headwinds and project cancellations, a robust sales pipeline and improved operational efficiencies support a positive outlook for 2025 and beyond.
hVIVO Earnings release: H1 2025
hVIVO released its H1 2025 earnings on July 22, 2025, summarizing the period's financial results.
hVIVO Earnings Call Transcript: H2 2024
Record revenue and EBITDA growth achieved, with strong cash reserves and expanded service offerings through acquisitions. Guidance for 2025 remains robust, despite macro headwinds and a temporary margin dip due to integration costs. Regulatory milestones and a diversified pipeline support long-term growth.